Again, very similar to Mr. Kavanagh, I'd say look at what happened with Eli Lilly. Two Canadian courts looked at their patents and said there was no real new utility and said it should go generic. They've said, under investor-state, that you don't have to really show new utility, you have to show a “scintilla” of utility. I think the problem is, who rules, who determines? We're a sovereign nation, very sophisticated, and I think our Canadian courts should be allowed to decide if a drug should be patented or if it should be considered generic.
On September 28th, 2016. See this statement in context.